País: Malta
Idioma: inglés
Fuente: Malta Medicines Authority
methylphenidate hydrochloride 10 mg
Novartis Pharmaceuticals UK Limited
N06BA04
methylphenidate hydrochloride
tablet
Authorised
2006-11-10
Page 1 of 16 PACKAGE LEAFLET: INFORMATION FOR THE USER RITALIN, 10 MG TABLETS METHYLPHENIDATE The name of your medicine is Ritalin, it contains the active substance ‘methylphenidate hydrochloride’. The name ‘methylphenidate’ will also be used in this leaflet. IMPORTANT THINGS YOU NEED TO KNOW ABOUT YOUR MEDICINE THIS MEDICINE IS USED TO TREAT ADHD The full name for ADHD is ‘Attention Deficit Hyperactivity Disorder’. The medicine helps with your brain activity. It can help improve your attention, help you concentrate, and make you less impulsive. You need to have other treatments for ADHD as well as this medicine. THIS MEDICINE IS ALSO USED TO TREAT NARCOLEPSY It helps to manage excessive daytime sleepiness. Read Section 1 for more information. BEFORE YOU TAKE THIS MEDICINE, TALK TO YOUR DOCTOR IF: You have heart, circulation, or mental health problems - you may not be able to take this medicine. You are taking any other medicines - this is because methylphenidate can affect how other medicines work. Read Section 2 for more information. WHILE TAKING THIS MEDICINE: See your doctor regularly. This is because your doctor will want to check how the medicine is working. Do not stop taking the medicine without first talking to your doctor. Your doctor may stop your medicine to see if it is still needed, if you take it for more than a year. The most common side effects are feeling nervous, not being able to sleep or having a headache. Read Sections 3 and 4 for more information. TALK TO YOUR DOCTOR STRAIGHT AWAY IF ANY OF THE FOLLOWING HAPPEN: Your mood and how you feel changes. You feel any problems with your heart. Read Section 4 for more information. Page 2 of 16 THE REST Leer el documento completo
2012-10-19 Lista ta’ kontroll għall-monitoraġġ ta’ terapija kontinwu Ottubru 2012 Lista ta’ kontroll 2: Lista ta’ kontroll għal methylphenidate (MPH) għall- monitoraġġ ta’ terapija kontinwu Dan li ġej huwa maħsub sabiex jgħinek fil-monitoraġġ ta’ terapija kontinwa ta’ prodott li jkun fih MPH fil-pazjenti b’disturb ta' nuqqas ta' attenzjoni/attività eċċessiva (attention-deficit/hyperactivity disorder - ADHD). Kif spjegat f’aktar dettall fl-informazzjoni dwar il-preskrizzjoni, l-istatus tal-iżvilupp, dak psikjatriku u dak kardjovaskulari għandhom jiġu mmonitorjati tajjeb: • Il-pressjoni tad-demm u l-polz għandhom jiġu rreġistrati kull darba li tiġi aġġustata d- doża u mbagħad mill-inqas kull 6 xhur • It-tul, il-piż u l-aptit għandhom jiġu rreġistrati mill-inqas kull 6 xhur biż-żamma ta’ ċart tal-iżvilupp • L-iżvilupp ta’ disturbi psikjatriċi _de novo_ jew l-aggravar ta’ disturbi psikjatriċi diġà eżistenti għandu jkun immonitorjat kull darba li tiġi aġġustata d-doża u mbagħad mill-inqas kull 6 xhur u waqt kull viżta Huwa rrakkomandat li din il-lista ta’ kontroll tintuża flimkien mal-informazzjoni sħiħa dwar il-preskrizzjoni għall-prodott individwali li jkun qed jiġi preskritt. Jekk jogħġbok niżżel u stampa din il-lista ta’ kontroll qabel il-konsultazzjoni tiegħek. Ma tistax taħżen xi informazzjoni speċifika dwar il-pazjenti fuq is-sit elettroniku. Il-lista ta’ kontroll mimlija tista’ titqiegħed mar-rekords tal-pazjent. Inti u timla l-lista ta’ kontroll, jista’ jkun utli wkoll li tiddiskuti l-fuljett ta’ tagħrif għall- pazjent (PIL) tal-prodott individwali li tkun qed tippreskrivi mal-pazjent u mal-ġenitur(i) jew tutur(i) tiegħu. 1 2012-10-19 Lista ta’ kontroll għall-monitoraġġ ta’ terapija kontinwu MONITORAĠĠ WAQT IL-KURA KONTINWA B’MPH Data tal-eżami: Leer el documento completo